相关实验视频
Updated: Jan 11, 2026

08:43
Investigating Intestinal Inflammation in DSS-induced Model of IBD
Published on: February 1, 2012
68.7K
拜通可以通过调节STING和JAK/STAT通路来改善DSS诱导的大肠炎
Yuhang Zhou1,2, XiaoXian Wang1, Jingxing Lyu1,2
1Department of Pharmacy, Wuhan No. 1 Hospital, Wuhan 430022, China.
ACS omega
|November 10, 2025
概括
百通 (BTD) 通过减少炎症和恢复肠道健康,有效治疗小鼠的性结肠炎 (UC). 这种传统中医药调节关键的炎症通路,为临床使用提供了潜力.
科学领域:
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
- 传统中国医药 传统中国医药
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病,治疗选择有限.
- 传统中医药百通 (BTD) 在UC中的治疗机制尚不清楚.
研究的目的:
- 为了研究BTD的治疗效果和潜在机制,用硫酸 (DSS) 诱导的UC的小鼠模型来研究BTD.
主要方法:
- 使用高性能液态染色学 (HPLC) 标准化的BTD化学特征.
- 评估了UC症状,结肠损伤和炎症标志物 (细胞因子,MPO活性).
- 利用网络药理学,分子对接,西方抹杀,ELISA和免疫组织化学 (IHC) 来探索信号通路.
主要成果:
- BTD显著改善了UC症状,包括体重减轻,疾病活动和结肠病理.
- BTD恢复了杯状细胞数量和粘液分泌,减少了促炎细胞因子 (TNF-α,IL-1β,IL-6,IL-18) 和MPO活性.
- 在体内,BTD抑制了NF-κB p65和IL-6的表达,并抑制了JAK/STAT和STING信号通路.
结论:
- 通过抑制炎症反应,BTD显示出对UC的显著治疗潜力.
- BTD调节JAK/STAT和STING信号通路,为其在UC治疗中的临床应用提供了机制基础.
更多相关视频
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
12.7K
09:04DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
Published on: February 27, 2014
48.5K
相关概念视频
The JAK-STAT Signaling Pathway
11.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
11.9K
Drugs for Treatment of Diarrhea-Predominant IBS
612
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
612